morning, quarter earnings XXXX Vivian, and fourth good conference Thank Welcome everyone. Nuwellis to you, call.
strategic give and will an overview full and performance, fourth initiatives. I our an quarter call, today's provide On update on our year of
by the questions, Blake, financial provide Lynn detailed results then followed before remarks. call opening Our closing Chief Financial Officer, for my will
increased an revenue proved in and Critical fourth to in XX% segment, of year-over-year. the the led a growth year-over-year Nuwellis in was Failure of XX% growth by XX% XX% our be revenue sequential segment. growth Heart revenue This the in full our our growth followed for year. X% Care growth increase by XXXX quarter, growth XX% Revenue was which Pediatric quarter with for year and a segment
Our mentioned that past. fueled the be execution growth have we to momentum of by strategies in key two continues the
our field our or organization, the expansion First, education in specialists, with clinical especially CESs.
played CESs provide within will more our role an inpatient outpatient important the Our facility, in call. supporting later the I account detail and and managers
The months last of the all that three of use momentum in the business. fueled second Aquadex initiative in the QX body our segments our supporting is X growing in evidence the the clinical of
to key guidelines update growing strategic like clinical for doing overload now we adoption. turn having business a of to I'd fluid the on and area Aquadex evidence. body practice to leverage towards more have with clinical change evidence. at driving investment standard A making Nuwellis, so, is an key for initiatives, robust the clinical us, care our further In our starting of
pediatrics and throughout many further are to technology to in and thus heart XXXX. surgery, reinforcing We in be announce cardiac new Nuwellis reviewed XXXX presentations poster pleased data conferences at medical publications, failure peer and far able
cabbage, coronary have clinical reviewed following two patients. new a at use XX data On post-operative demonstrating cardiac survival publication the bypass mentioned, days peer ultrafiltration artery we announced grafting, previously of publications. of As we XX, peer high-risk in surgery, XXX% August review the or
included surgery, to ultrafiltration a protocol term key on annals hospital authors the diuretics. In or recommendation post-cardiac unresponsive surgery associated order acute kidney a this injury commented year, of patients that use January cardiac set surgery thoracic to for of that for the are
goal is change to evidence of body practice for improve our post-cardiac to and supportive outcomes This ultrafiltration. to guidelines of recommendation validate our our Aquadex leverage therapy surgery clinical
strong was Meeting that multicenter the benefit Heart called Failure at called AVOID-HF over days, Scientific unresponsive the newly failure Heart statistical Win at patients XXXX diuretics. segment, Ratios. favored we highlighted presented showed new in included the In the This diuretics America Failure events randomized analysis of analyzed controlled under and of trial overload analysis Society who and reducing ultrafiltration heart XX are XX the heart to cardiovascular failure mortality clinical
consecutive days. average demonstrated heart announced in year a failure XX% reviewed of hospitalizations addition, XX lower real-world decrease fourth in per a failure a and The national year the study In rehospitalizations the publication a of heart after XX-year the quarter, retrospective Aquadex. single hospitalization XX% we of peer lower readmissions center data supporting and in from XXX using patients
facilities data this leveraging inpatient actively Nuwellis savings in of the both Aquadex and in with and outpatient the system provide economic now benefit well as to providers the the quality use improved life educate are of as setting, We patients. can and cost of
We make also our pivotal REVERSE-HF continue to progress on trial.
comparison our REVERSE-HF As activated of evaluate events days the date, point reminder, a primary end the To achieve first of clinical between are QX sites within diuretics. the quarter. loop and therapy track heart end we and XX XXXX milestone XX the of by Aquadex on will effectiveness enrolled intravenous as study mortality XX and have to nine and failure we sites
We expect medical of this to to present societies guidelines. for study responsible establishing results the the medical
birthweight XX% therapy announced the preterm demonstrating our Pediatrics, used low in of in segment we peer-reviewed Aquadex in in fastest-growing survival neonates. data replacement Further, kidney business,
him completing to to continue I decades brings of our to adult two expertise, team program, heart Jeffries and clinical our we evidence. him both with Dr. my in failure like Jeffries, extend John warm build welcome to Medical And body our are cardiology patients. of Chief over would clinical and pediatric Finally, Officer. as excited our new have Dr. we
of and includes of strategic penetration. footprint both targeted to second expansion team our base involve our initiatives Our of accounts. commercial active drive installed This commercial expansion the our
able end account we all the have management that education QX, positions. sales say As open pleased are filled be of we clinical now of to to leadership, and
in on all CES, with specialists, the facilitate In but hospital the so patient of support use or also only system. helping clinical nurses, they addition doing, optimal adoption whom ultrafiltration specialty As not of our team to our education are new multiple in use patient facilities. successful of previously directly at partner units therapy care outcomes, targeted trained noted, our the increased drive across
record in key East in date, U.S. for Coast centers. and focused As razor the we prior increased razor the of We in with sales placements, our have more and strong console base, versus with model, our quarter Xx expansion in the to the our installed XXXX consoles fourth console compared increased blade sold. ago year expansion the period foot than XX% achieved XX locations and in in year QX in established a geographic high-volume To U.S.
real-world our clinics initiative is extremely studies we failure patients patients. due the treating now Through costly to cost current readmission care, of for managing care Turning to strategic both third of and and research, of hospitals found targeting many our failure have that suggest case standard rates. fluid outpatient higher overload, patients hospital heart heart high
data, days. of the patient within cost for treat days, hospital $XX,XXX patient to to encounter over unreimbursed failure to hospitalized a per XX readmissions per average the cost heart According it X in addition of
thereby hospitalization. both lower have reduces heart heart the As Aquadex XX%, clinical and total decreasing hospitalization and unreimbursed demonstrating the of by that over mentioned cost XX% by failure failure we of evidence the care rates readmission before, now cost
Category American Association Medical in CPT of milestone therapeutic of was Nuwellis dedicated code the assignment ultrafiltration. the by major X new 'XX a Another for
We code lack using clinics use reactivate our who have reimbursement. in conversations due discontinued had the been been but leveraging this of to previously later outpatient Aquadex to
three sight line a to believe benefit leverage two to achieving there providers of of CPT Nuwellis that the continue toward X allow for is We a to of which years, Aquadex alike. will facilities Category our code in and further goal
distribution product front partnerships. which as I an well Selective pediatric fourth now Cytopheretic Device, on recent agreement for Medical's or begin for SeaStar announced update is exclusive strategic acute on Turning will kidney as strategic development to licensing SCD, the U.S. our injury. preventive with our initiative, the and
restore decision pediatric demonstrated on more to ICU segment time dependency further critical this enabling further have lives also us pediatric underserved and eliminate focus portfolio agreement reinforces This patient lives to dialysis in our the of our shorten studies Clinical potential SCD's product the communicated previously expand population. that and to patients. and EO save
complete Medical weeks a for its or its children review in year. the SCD in to FDA the to updated We and look of forward HDE, Humanitarian use the you expects keeping the this of Device coming Extension, on of in the SeaStar half first progress months.
be need therapy patient from noting physicians, a could On treatment. track we XXXX. addresses how anticipate the and the are been continuous our potentially by and progress have our particular, development replacement device pediatric renal to continue IDE on unmet in population and this nephrologists early feedback game product in enthusiastic, changer uniquely Early of on submission pediatric pediatric technology with front,
am to reiterate In the Nuwellis. for future I I of conclusion, want excited how
fluid for work we We making Our this goal I goal. continue path, Aquadex restoring are towards approaching strong did and balance care The forward of beyond. standard and remains XXXX execution look therapy, intact. XXXX believe to this in the a inflection us that down reaching point an advanced we of in
Lynn call I discuss and our the our Blake, Now full XXXX would QX Chief like to year Financial turn results. over Officer, to to
